Mycobacterium avium subspecies paratuberculosis (MAP) infection, and its impact on gut microbiome of individuals with multiple sclerosis.
Gut microbiome; 16S rRNA
Mediation analysis; Neutral modelling
Multiple sclerosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 10 2024
14 10 2024
Historique:
received:
07
02
2024
accepted:
30
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
The microbial ecology of Mycobacterium avium subspecies paratuberculosis infections (MAP) within the context of Multiple Sclerosis (MS) is largely an unexplored topic in the literature. Thus, we have characterized the compositional and predicted functional differences of the gut microbiome between MS patients with MAP (MAP+) and without (MAP-) infection. This was done in the context of exposome differences (through self-reported filled questionnaires), principally in anthropometric and sociodemographic patterns to gain an understanding of the gut microbiome dynamics. 16S rRNA microbiome profiling of faecal samples (n = 69) was performed for four groups, which differed by disease and MAP infection: healthy cohort (HC) MAP-; HC MAP+ ; MS MAP-; and MS MAP+ . Using a dynamic strategy, with MAP infection and time of sampling as occupancy models, we have recovered the core microbiome for both HC and MS individuals. Additional application of neutral modeling suggests key genera that are under selection pressure by the hosts. These include members of the phyla Actinobacteriota, Bacteroidota, and Firmicutes. As several subjects provided multiple samples, a Quasi Conditional Association Test that incorporates paired-nature of samples found major differences in Archaea. To consolidate treatment groups, confounders, microbiome, and the disease outcome parameters, a mediation analysis is performed for MS cohort. This highlighted certain genera i.e., Sutterella, Akkermansia, Bacteriodes, Gastranaerophilales, Alistipes, Balutia, Faecalibacterium, Lachnospiraceae, Anaerostipes, Ruminococcaceae, Eggerthellaceae and Clostridia-UCG-014 having mediatory effect using disease duration as an outcome and MAP infection as a treatment group. Our analyses indicate that the gut microbiome may be an important target for dietary and lifestyle intervention in MS patients with and without MAP infection.
Identifiants
pubmed: 39402079
doi: 10.1038/s41598-024-74975-4
pii: 10.1038/s41598-024-74975-4
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24027Subventions
Organisme : Engineering and Physical Sciences Research Council
ID : EP/V030515/1
Informations de copyright
© 2024. The Author(s).
Références
Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult. Scler. J. 26(14), 1816–1821 (2020).
doi: 10.1177/1352458520970841
WHO. Multiple sclerosis: World Health Organization. https://www.who.int/news-room/fact-sheets/detail/multiple-sclerosis (2023).
Olsson, T., Barcellos, L. F. & Alfredsson, L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 13(1), 25–36 (2017).
pubmed: 27934854
doi: 10.1038/nrneurol.2016.187
Ekundayo, T. C. et al. Systematic review and meta-analysis of Mycobacterium avium subsp. paratuberculosis as environmental trigger of multiple sclerosis. Mult. Scler. Relat. Disord. 59, 103671 (2022).
pubmed: 35180618
doi: 10.1016/j.msard.2022.103671
Hayashi, F. et al. Elevated mycobacterium avium subsp paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis. J. Neuroimmunol. 360, 577701 (2021).
pubmed: 34507015
doi: 10.1016/j.jneuroim.2021.577701
Eslami, M. et al. Mycobacterium avium paratuberculosis and Mycobacterium avium complex and related subspecies as causative agents of zoonotic and occupational diseases. J. Cell. Physiol. 234(8), 12415–12421 (2019).
pubmed: 30673126
doi: 10.1002/jcp.28076
Harris, N. B. & Barletta, R. G. Mycobacterium avium subsp. paratuberculosis in veterinary medicine. Clin. Microbiol. Rev. 14(3), 489–512 (2001).
pubmed: 11432810
pmcid: 88986
doi: 10.1128/CMR.14.3.489-512.2001
O’shea, B. et al. Amplified fragment length polymorphism reveals genomic variability among Mycobacterium avium subsp. paratuberculosis isolates. J. Clin. Microbiol. 42(8), 3600–3606 (2004).
pubmed: 15297504
pmcid: 497631
doi: 10.1128/JCM.42.8.3600-3606.2004
Sechi, L. A. et al. Mycobacterium avium subspecies paratuberculosis bacteremia in type 1 diabetes mellitus: an infectious trigger?. Clin. Infect. Dis. 46(1), 148–149 (2008).
pubmed: 18171233
doi: 10.1086/524084
Manca Bitti, M. L. et al. Mycobacterium avium subsp. paratuberculosis in an Italian cohort of type 1 diabetes pediatric patients. J. Immunol. Res. 2012, 1–5 (2012).
Naser, S. A., Ghobrial, G., Romero, C. & Valentine, J. F. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn’s disease. Lancet 364(9439), 1039–1044 (2004).
pubmed: 15380962
doi: 10.1016/S0140-6736(04)17058-X
Arru, G. et al. Is there a role for Mycobacterium avium subspecies paratuberculosis in Parkinson’s disease?. J. Neuroimmunol. 293, 86–90 (2016).
pubmed: 27049567
doi: 10.1016/j.jneuroim.2016.02.016
Cannas, S., Mura, M., Dettori, G., Fadda, G. & Zanetti, S. Detection and isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn’s disease in Sardinia. Am. J. Gastroenterol. 100(7), 1529–1536 (2005).
pubmed: 15984976
doi: 10.1111/j.1572-0241.2005.41415.x
Cossu, D. et al. Association of Mycobacterium avium subsp. paratuberculosis with multiple sclerosis in Sardinian patients. PLoS One 6(4), e18482 (2011).
pubmed: 21533236
pmcid: 3076380
doi: 10.1371/journal.pone.0018482
Lane, J., Shin Ng, H., Poyser, C., Lucas, R. M. & Tremlett, H. Multiple sclerosis incidence: A systematic review of change over time by geographical region. Mult. Scler. Relat. Disord. 63, 103932 (2022).
pubmed: 35667315
doi: 10.1016/j.msard.2022.103932
Cossu, D. et al. Association of Mycobacterium avium subsp. paratuberculosis and SLC11A1 polymorphisms in Sardinian multiple sclerosis patients. J. Infect. Dev. Ctries. 7(3), 203–207 (2013).
pubmed: 23492997
doi: 10.3855/jidc.2737
Cossu, D. et al. Anti Mycobacterium avium subsp. paratuberculosis heat shock protein 70 antibodies in the sera of Sardinian patients with multiple sclerosis. J. Neurol. Sci. 335(1–2), 131–133 (2013).
pubmed: 24075312
doi: 10.1016/j.jns.2013.09.011
Sechi, L. A. et al. Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paratuberculosis lend support to the infectious trigger hypothesis. Clin. Vaccine Immunol. 15, 320–326 (2008).
pubmed: 18077612
doi: 10.1128/CVI.00381-07
Klindworth, A. et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res. 41(1), e1 (2013).
pubmed: 22933715
doi: 10.1093/nar/gks808
Ijaz, U. Z. et al. Comprehensive longitudinal microbiome analysis of the chicken cecum reveals a shift from competitive to environmental drivers and a window of opportunity for Campylobacter. Front. Microbiol. 9, 2452 (2018).
pubmed: 30374341
pmcid: 6196313
doi: 10.3389/fmicb.2018.02452
Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41(D1), D590–D596 (2012).
pubmed: 23193283
pmcid: 3531112
doi: 10.1093/nar/gks1219
Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7(5), 335–336 (2010).
pubmed: 20383131
pmcid: 3156573
doi: 10.1038/nmeth.f.303
Douglas, G. M. et al. PICRUSt2 for prediction of metagenome functions. Nat. Biotechnol. 38(6), 685–688 (2020).
pubmed: 32483366
pmcid: 7365738
doi: 10.1038/s41587-020-0548-6
Ijaz, U. Z. et al. Speciality grand challenge: How can we use integrative approaches to understand microbial community dynamics?. Front. Syst. Biol. 4, 1432791 (2024).
doi: 10.3389/fsysb.2024.1432791
Sadovnick, A., Paty, D. & Yannakoulias, G. Concurrence of multiple sclerosis and inflammatory bowel disease. N. Engl. J. Med. 321(11), 762–763 (1989).
pubmed: 2770807
doi: 10.1056/NEJM198909143211115
Gupta, G., Gelfand, J. M. & Lewis, J. D. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129(3), 819–826 (2005).
pubmed: 16143121
doi: 10.1053/j.gastro.2005.06.022
Langer-Gould, A., Albers, K., Van Den Eeden, S. & Nelson, L. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult. Scler. J. 16(7), 855–861 (2010).
doi: 10.1177/1352458510369146
Marrie, R. A. et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult. Scler. J. 21(3), 282–293 (2015).
doi: 10.1177/1352458514564490
Yang, Y. et al. Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases. Nat. Commun. 12(1), 5641 (2021).
pubmed: 34561436
pmcid: 8463615
doi: 10.1038/s41467-021-25768-0
Feller, M. et al. Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect. Dis. 7(9), 607–613 (2007).
pubmed: 17714674
doi: 10.1016/S1473-3099(07)70211-6
Uzoigwe, J. C., Khaitsa, M. L. & Gibbs, P. Epidemiological evidence for Mycobacterium avium subspecies paratuberculosis as a cause of Crohn’s disease. Epidemiol. Infect. 135(7), 1057–1068 (2007).
pubmed: 17445316
pmcid: 2870686
doi: 10.1017/S0950268807008448
Naser, S. A., Sagramsingh, S. R., Naser, A. S. & Thanigachalam, S. Mycobacterium avium subspecies paratuberculosis causes Crohn’s disease in some inflammatory bowel disease patients. World J. Gastroenterol. 20(23), 7403 (2014).
pubmed: 24966610
pmcid: 4064085
doi: 10.3748/wjg.v20.i23.7403
Ventura, R. et al. Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course. Sci. Rep. 9(1), 16396 (2019).
pmcid: 6841666
doi: 10.1038/s41598-019-52894-z
Tremlett, H. et al. Gut microbiota in early pediatric multiple sclerosis: a case−control study. Eur. J. Neurol. 23(8), 1308–1321 (2016).
pubmed: 27176462
doi: 10.1111/ene.13026
Chen, J. et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci. Rep. 6(1), 28484 (2016).
pubmed: 27346372
pmcid: 4921909
doi: 10.1038/srep28484
Shetty, S. A., Hugenholtz, F., Lahti, L., Smidt, H. & de Vos, W. M. Intestinal microbiome landscaping: insight in community assemblage and implications for microbial modulation strategies. FEMS Microbiol. Rev. 41(2), 182–199 (2017).
pubmed: 28364729
pmcid: 5399919
doi: 10.1093/femsre/fuw045
Shade, A. & Stopnisek, N. Abundance-occupancy distributions to prioritize plant core microbiome membership. Curr. Opin. Microbiol. 49, 50–58 (2019).
pubmed: 31715441
doi: 10.1016/j.mib.2019.09.008
Jangi, S. et al. Alterations of the human gut microbiome in multiple sclerosis. Nat. Commun. 7(1), 12015 (2016).
pubmed: 27352007
pmcid: 4931233
doi: 10.1038/ncomms12015
Huang, Y., Wu, M., Xiao, H., Liu, H. & Yang, G. Mesalamine-mediated amelioration of experimental colitis in piglets involves gut microbiota modulation and intestinal immune cell infiltration. Front. Immunol. 13, 883682 (2022).
pubmed: 35898495
pmcid: 9309220
doi: 10.3389/fimmu.2022.883682
Ochoa-Repáraz, J., Kirby, T. O. & Kasper, L. H. The gut microbiome and multiple sclerosis. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a029017 (2018).
doi: 10.1101/cshperspect.a029017
pubmed: 29311123
pmcid: 5983160
Zhang, Y. et al. Dietary type 2 resistant starch improves systemic inflammation and intestinal permeability by modulating microbiota and metabolites in aged mice on high-fat diet. Aging 12(10), 9173 (2020).
pubmed: 32452830
pmcid: 7288951
doi: 10.18632/aging.103187
Jiang, W. et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci. Rep. 5(1), 8096 (2015).
pubmed: 25644696
pmcid: 4314632
doi: 10.1038/srep08096
Anderson, J. R. et al. A preliminary examination of gut microbiota, sleep, and cognitive flexibility in healthy older adults. Sleep Med. 38, 104–107 (2017).
pubmed: 29031742
pmcid: 7433257
doi: 10.1016/j.sleep.2017.07.018
Navarro-López, V. et al. Gut microbiota as a potential predictive biomarker in relapsing-remitting multiple sclerosis. Genes 13(5), 930 (2022).
pubmed: 35627315
pmcid: 9140870
doi: 10.3390/genes13050930
Choileáin, S. N. et al. CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome. J. Transl. Autoimmun. 3, 100032 (2020).
pubmed: 32743517
doi: 10.1016/j.jtauto.2019.100032
Moles, L. et al. Microbial dysbiosis and lack of SCFA production in a Spanish cohort of patients with multiple sclerosis. Front. Immunol. 13, 960761 (2022).
pubmed: 36325343
pmcid: 9620961
doi: 10.3389/fimmu.2022.960761
Barone, M. et al. Influence of a high-impact multidimensional rehabilitation program on the gut microbiota of patients with multiple sclerosis. Int. J. Mol. Sci. 22(13), 7173 (2021).
pubmed: 34281224
pmcid: 8268819
doi: 10.3390/ijms22137173
Boullerne, A. I. et al. Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity. J. Neuroimmunol343, 577237 (2020).
pubmed: 32289594
pmcid: 7301750
doi: 10.1016/j.jneuroim.2020.577237
Zafar, H. & Saier, M. H. Jr. Gut bacteroides species in health and disease. Gut Microbes 13(1), 1848158 (2021).
pubmed: 33535896
pmcid: 7872030
doi: 10.1080/19490976.2020.1848158
Glover, J. et al. Elucidating the role of Acinetobacter calcoaceticus in promoting intestinal inflammation. Physiology 38(S1), 5734284 (2023).
doi: 10.1152/physiol.2023.38.S1.5734284
Derrien, M., Vaughan, E. E., Plugge, C. M. & de Vos, W. M. Akkermansia muciniphila gen. nov., sp. Nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 54(5), 1469–1476 (2004).
pubmed: 15388697
doi: 10.1099/ijs.0.02873-0
Ebringer, A. et al. Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens?. Environ. Health Perspect. 105(11), 1172–1174 (1997).
pubmed: 9370514
pmcid: 1470340
doi: 10.1289/ehp.971051172
Allerberger F, Berger T, Reindl M. Anti-Acinetobacter and anti-neuronal antibodies in Austrian patients with multiple sclerosis and other neurological diseases. J Neurol.
Ebringer, A., Hughes, L., Rashid, T. & Wilson, C. Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch. Neurol. 62(1), 33–36 (2005).
pubmed: 15642847
doi: 10.1001/archneur.62.1.33
Yang, Q. et al. Identification of an intestinal microbiota signature associated with the severity of necrotic enteritis. Front. Microbiol. 12, 703693 (2021).
pubmed: 34489892
pmcid: 8418326
doi: 10.3389/fmicb.2021.703693
Bose, T., Venkatesh, K. & Mande, S. S. Investigating host-bacterial interactions among enteric pathogens. BMC Genom. 20, 1–16 (2019).
doi: 10.1186/s12864-019-6398-2
Schirmer, M., Garner, A., Vlamakis, H. & Xavier, R. J. Microbial genes and pathways in inflammatory bowel disease. Nat. Rev. Microbiol. 17(8), 497–511 (2019).
pubmed: 31249397
pmcid: 6759048
doi: 10.1038/s41579-019-0213-6
Pereira, C. A. P. Microbiota intestinal humana y dieta. Cienc. Tecnol. 12(1), 31–42 (2019).
doi: 10.18779/cyt.v12i1.315
Victoria, M. et al. Gut microbiota alterations in critically ill older patients: a multicenter study. BMC Geriatr. 22(1), 1–12 (2022).
doi: 10.1186/s12877-022-02981-0
Chiodini, R. J. et al. Microbial population differentials between mucosal and submucosal intestinal tissues in advanced Crohn’s disease of the ileum. PloS One 10(7), e0134382 (2015).
pubmed: 26222621
pmcid: 4519195
doi: 10.1371/journal.pone.0134382
Hirano, A. et al. Comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 33(9), 1590–1597 (2018).
doi: 10.1111/jgh.14129
Humbel, F. et al. Association of alterations in intestinal microbiota with impaired psychological function in patients with inflammatory bowel diseases in remission. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2019.09.022 (2020).
doi: 10.1016/j.cgh.2019.09.022
pubmed: 31546058
Vujkovic-Cvijin, I. et al. Host variables confound gut microbiota studies of human disease. Nature 587(7834), 448–454 (2020).
pubmed: 33149306
pmcid: 7677204
doi: 10.1038/s41586-020-2881-9
Lin, Y. et al. Combing fecal microbial community data to identify consistent obesity-specific microbial signatures and shared metabolic pathways. Iscience 26(4), 106476 (2023).
pubmed: 37096041
pmcid: 10122048
doi: 10.1016/j.isci.2023.106476